Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,438 signal articles · 135 in last 24h · 154,019 total before filter · latest 56m ago
135last 24h
869last 7d
144● bullish (7d)
99● bearish (7d)
214publishers
AllMacro207Earnings105M&A125Regulatory22Product21Analyst16
✕ clear all filtersticker: PFESentiment:bullishneutralbearishshow all (incl. clickbait)
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval
Reuters71d agobearish
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval

July 15 () - Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch ‌of its newly approved breast cancer drug and treatment-tolerability ‌concerns overshadowed the company's first U. Food and Drug Administration on ​Tuesday approved gedatolisib, branded as Revtorpyk, for certain patients with advanced breast cancer whose tumors do not carry a PIK3CA mutation.